Purple Biotech Q1 2026 Results Highlight CAPTN-3 Pivot and IM1240 Preclinical Momentum

Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Purple Biotech ( (PPBT) ) just unveiled an announcement. On May 15, 2026, Purple Biotech reported first-quarter 2026 results and highlighted progress on its CAPTN-3 tri-specific antibody platform, including new preclinical data showing potent anti-tumor activity of lead candidate IM1240 in treatment-resistant, patient-derived tumor samples, such as PD-1-resistant head and neck cancer and bladder cancer, as well as induction of favorable immune structures in non-small cell lung cancer tissue. The company also formed a CAPTN-3-focused scientific advisory board, expanded an AI-driven discovery collaboration with Converge Bio, redirected resources from legacy programs CM24 and NT219 to prioritize CAPTN-3, and ended the quarter with $6.4 million in cash expected to fund operations into 2027, reporting a modest net loss of $0.1 million driven down by higher finance income despite rising R&D and G&A expenses. Research and development expenses rose to $1.2 million in the quarter, reflecting increased chemistry, manufacturing, and controls investment for CAPTN-3, while general and administrative costs climbed to $1.0 million on higher payroll and professional fees. Although adjusted operating and net losses widened to $2.1 million, non-cash warrant-related finance income of $2.2 million materially offset operating losses, underscoring that Purple Biotech’s near-term financial profile remains constrained but its extended cash runway and intensified focus on CAPTN-3 mark a strategic pivot toward its most differentiated immunotherapy assets and could be significant for investors tracking next-generation T-cell engager platforms in solid tumors. The most recent analyst rating on (PPBT) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page. Spark’s Take on PPBT Stock According to Spark, TipRanks’ AI Analyst, PPBT is a Neutral. The score is held down primarily by weak financial performance (minimal revenue, widening losses, and continued cash burn alongside a shrinking equity base). Technicals are also bearish with negative momentum and price below key moving averages, only partially offset by oversold signals. Valuation contributes little support due to unprofitability and no dividend data. To see Spark’s full report on PPBT stock, click here. More about Purple Biotech Purple Biotech Ltd. is a clinical-stage biotechnology company based in Rehovot, Israel, focused on next-generation cancer immunotherapies. Its core CAPTN-3 platform comprises masked tri-specific antibodies designed to activate T cells and NK cells selectively within the tumor microenvironment, led by IM1240 approaching the clinic and IM1305 in preclinical development, alongside partnered-dependent legacy assets CM24 and NT219. Average Trading Volume: 13,550 Technical Sentiment Signal: Strong Sell Current Market Cap: $6.4M